fda glp-1 Pharmacovigilance Assessment of Compounded Receptor Agonists: Insights From the Adverse Event Reporting System GLP-1 Injections for Medical Weight

Consequently, on top of the beneficial effect of weight loss caused by GLP-1 analogues these drugs also cause a substantial reduction of the glycemic load (GL = carbohydrate intake X Glycemic index), which per se reduces hyperinsulinemia and causes weight loss [22], reduce diabetes risk [23], inflammation [24], and cardiovascular risk [25]

Since then, Musk has become a big proponent of GLP-1 medications

Glucagon-like peptide-1 receptor agonist protects against hyperglycemia-induced cardiocytes injury by inhibiting high mobility group box 1 expression

The 2.5mg starting dose is subtherapeutic for weight loss

While the first GLP-1 was approved by the FDA more than 20 years ago, to treat Type 2 diabetes, the use of these drugs took off in 2021 when Novo Nordisk received approval for a semaglutide drug to treat obesity, with the brand name Wegovy

Essentially, GLP-1 helps your body manage glucose efficiently and naturally supports healthy weight management